NYSEAMERICAN:AMPEAmpio Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ampio Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.11 +0.06 (+5.71 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$1.04Now: $1.11▼$1.1650-Day Range N/A52-Week Range$0.26Now: $1.11▼$1.24Volume2.67 million shsAverage Volume2.26 million shsMarket Capitalization$182.98 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAmpio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Ampio Pharmaceuticals has a potential upside of 260.4% from its current price of $1.11.Amount of Analyst CoverageAmpio Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAmpio Pharmaceuticals has received 154 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmpio Pharmaceuticals has received 162 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmpio Pharmaceuticals has received 51.27% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote “Outperform” if you believe AMPE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmpio Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmpio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ampio Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSEAMERICAN:AMPE Previous SymbolNYSE:AMPE CUSIP03209T10 CIK1411906 Webampiopharma.com Phone+1-720-4376500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees22 Outstanding Shares164,851,000Market Cap$182.98 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $1.11 +0.06 (+5.71 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AMPE News and Ratings via Email Sign-up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Ampio Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ampio Pharmaceuticals. When is Ampio Pharmaceuticals' next earnings date? Ampio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Ampio Pharmaceuticals. How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) issued its quarterly earnings results on Wednesday, May, 6th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). View Ampio Pharmaceuticals' earnings history. What price target have analysts set for AMPE? 1 equities research analysts have issued twelve-month price targets for Ampio Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Ampio Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 260.4% from the stock's current price. View analysts' price targets for Ampio Pharmaceuticals. Has Ampio Pharmaceuticals been receiving favorable news coverage? News articles about AMPE stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ampio Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View the latest news about Ampio Pharmaceuticals. Who are some of Ampio Pharmaceuticals' key competitors? Some companies that are related to Ampio Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Ampio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Trevena (TRVN), Cerus (CERS), NovaBay Pharmaceuticals (NBY), AVEO Pharmaceuticals (AVEO), Athersys (ATHX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Protalix Biotherapeutics (PLX), Rigel Pharmaceuticals (RIGL) and Arena Pharmaceuticals (ARNA). Who are Ampio Pharmaceuticals' key executives? Ampio Pharmaceuticals' management team includes the following people: Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 67)Mr. Thomas E. Chilcott III, CFO, Treasurer & Sec. (Age 51)Ms. Holli Cherevka, Chief Operating Officer (Age 36) What is Ampio Pharmaceuticals' stock symbol? Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE." Who are Ampio Pharmaceuticals' major shareholders? Ampio Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.06%) and Chicago Partners Investment Group LLC (0.04%). View institutional ownership trends for Ampio Pharmaceuticals. Which major investors are selling Ampio Pharmaceuticals stock? AMPE stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View insider buying and selling activity for Ampio Pharmaceuticals. Which major investors are buying Ampio Pharmaceuticals stock? AMPE stock was bought by a variety of institutional investors in the last quarter, including Chicago Partners Investment Group LLC. View insider buying and selling activity for Ampio Pharmaceuticals. How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ampio Pharmaceuticals' stock price today? One share of AMPE stock can currently be purchased for approximately $1.11. How big of a company is Ampio Pharmaceuticals? Ampio Pharmaceuticals has a market capitalization of $182.98 million. Ampio Pharmaceuticals employs 22 workers across the globe. What is Ampio Pharmaceuticals' official website? The official website for Ampio Pharmaceuticals is ampiopharma.com. How can I contact Ampio Pharmaceuticals? Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
